Recent Articles from GlobeNewswire

ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications.

Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.

Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Phase lla, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of AUD, with six patients enrolled to date. Three participants have been enrolled at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C (“phase IIa”) following the successful completion of the trial’s initial safety part in healthy volunteers.

PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

Progress on share buyback programme

–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–

FRISCO, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Comstock Resources, Inc. (NYSE and NYSE Texas: CRK) ("Comstock" or the "Company") announced today that it has entered into a letter of intent with the State Oil Company of the Azerbaijan Republic ("SOCAR") under which SOCAR or a wholly owned subsidiary of SOCAR would acquire, subject to the terms of the letter of intent and a definitive purchase and sale agreement, (i) a non-operated working interest representing 20% of Comstock's interest in its Legacy Haynesville upstream assets, (ii) a non-operated working interest equal to 15% of Comstock's interest in its Western Haynesville upstream assets, reducing to 7.5% after five years and once SOCAR has achieved a 15% return on investment in those assets, and (iii) 15% of Comstock’s 73% ownership interest in Pinnacle Gas Services LLC, which provides midstream services to the Western Haynesville, for an aggregate purchase price of $1.65 billion in cash, subject to customary purchase price adjustments. The letter of intent binds the parties to negotiate in good faith a definitive purchase and sale agreement, with the parties targeting execution by October 31, 2026, and a closing by year end, in each case subject to the progress of negotiations. Closing will be subject to customary conditions, including any required government and third-party approvals. The transaction will have an effective date of July 1, 2026.

Richa Pareek, new Chief Product Officer, to Lead USBC’s Next Phase of Platform Development

Award-winning Capital Markets Executive to Lead Investor Strategy and Shareholder Engagement

BEIJING, Sept. 01, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced that Mr. Xu Chen (“Mr. Chen”) has ceased to act as the president of the Company (the “President”) by rotation with effect from September 1, 2026. Mr. Chen will remain as an executive director and has resumed the role of Chief Marketing Officer of the Company.

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.

Company to Present and Host 1x1 Investor Meetings on Tuesday and Wednesday, September 15th-16th, 2026

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

Adds AI-Enabled 3PL Warehouse Management and Omnichannel Fulfillment Capabilities to the Global Logistics Network

Launching September 1, Talking Tom Heroes: Suddenly Super makes its U.S. debut across streaming, toys, and gaming

Transaction in Own Shares

MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for GA secondary to dry age-related macular degeneration (dAMD). The Company also highlighted the recent FDA RMAT designation for OCU410, which supports a potential accelerated development and review pathway for the program.

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company. He will serve as Chairman and CEO of Invivyd going forward.

Poverty, respiratory infections, air pollution, and health care barriers make living with asthma more challenging

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

New MCP-Powered tool helps content and marketing, IT administrators, and multi-location operators manage everyday digital signage tasks faster and more easily

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:

MILAN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) with clinical programs in Usher syndrome type 1B and Stargardt disease enabled by its proprietary dual-AAV platform designed to overcome the AAV cargo capacity limit, today announced the appointment of Megan Zoschg Canniere, Pharm.D., as Chief Regulatory & Quality officer. Dr. Zoschg Canniere joins the Company’s leadership team to support the continued advancement of AAVantgarde’s clinical-stage pipeline and regulatory strategy and will report to Dr. Natalia Misciattelli, Chief Executive Officer.

Data to be presented in a mini-oral session will describe anti-tumor activity of BH-30643 in patients with secondary EGFR resistance mutations such as EGFR C797S 

CHICAGO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced management will participate in the following conference in September 2026:

ALACHUA, Fla. and TAMPA, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will be available for one-on-one investor meetings at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026.

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President and Chief Executive Officer Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.

WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:

Steve Falcone brings more than 30 years of operations, quality, and compliance leadership across global biopharmaceutical manufacturing

Fresh from multiple wins at the 2026 World Beer Awards, BrewDog brings a major new premium craft beer innovation to market through a nationwide retail rollout.

Immunocore to present at upcoming investor conferences

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that management will participate in the following upcoming investor conferences:

Acquisition expands ROC Evidence into an end-to-end investigative intelligence offering by combining proven digital forensics with digital evidence management

Dallas, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- – Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, announced today that it has entered into a binding offer to acquire eCential Robotics, a leading developer of enabling technologies and surgical robotics. The acquisition expands the ASTRA™ enabling technology platform with robotic automation capabilities, creating a more comprehensive ecosystem designed to improve surgical precision, streamline workflows, and enhance patient outcomes. 

HOUSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR) announced today its Mission Technology Solutions business, which will be Trinzic after its planned spin-off, will help keep the U.S. prepared for extreme weather following its award of the Commercial Data Program National Mesonet Program (CDP NMP) contract by the National Oceanic and Atmospheric Administration’s National Weather Service. The single-award follow-on contract has a ceiling value of $1.1 billion over five years, reflecting growing demand for weather data across missions and government customers.

Annualized payment volume reached approximately US$255 million, up from approximately US$93 million based on July activity

Member benefit provides a 15% tuition scholarship toward more than 400 ASU Online degree and certificate programs

BEIJING, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Luckin Coffee Inc. (“Luckin Coffee” or the “Company”) (OTC: LKNCY) today announced that its board of directors has approved the upsizing of the Company’s share repurchase program (the “Share Repurchase Program”). As previously disclosed, in April 2026, the Company launched the Share Repurchase Program, pursuant to which the Company was authorized to repurchase up to US$300 million of its Class A ordinary shares in the form of American depositary shares (“ADSs”) over a 12-month period from April 30, 2026 (the “Term of the Share Repurchase Period”). As of August 31, 2026, the Company had repurchased a total of 71.6 million Class A ordinary shares (equivalent to 8.9 million ADSs) for a total consideration of US$287.2 million under the Share Repurchase Program.

Full three-tier AI documentation lineup — AI Dictation, AI Scribe Core, and AI Scribe Pro — now available for ophthalmology and optometry practices

Vimo Brings Together Technology, Transformation Services, and Operational Expertise for Public Agencies

2026 China International Fair for Trade in Services

Medicel AG expands its SOFT TIP I/A portfolio  with the launch of BICEL™ SOFT TIP I/A terralution™ – bimanual sustainable I/A (irrigation / aspiration) for gentle tissue interaction – at the ESCRS Congress 2026 in London.

Chicago, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The Chicago School announced the inaugural recipients of its Clinical Psychology Impact Fellowship, a prestigious full-tuition fellowship created to support incoming Doctor of Psychology (Psy.D.) students dedicated to advancing public mental health through clinical excellence, leadership, and service. The fellowship’s full tuition support makes graduate education more accessible while preparing fellows to create greater impact in communities and across the country.

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- OPPEIN has been recognized by Frost & Sullivan as the Global No. 1 Brand in the Customized Home Furnishings Market in 2025, further reinforcing the company's position as a leading provider of whole-house customization solutions. The recognition is based on a rigorous assessment of the brand's overall business performance and market presence, underscoring OPPEIN's sustained growth and expanding global footprint.

Ingelheim, Germany, and Bracknell, United Kingdom

Jersey City, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- The catastrophe modeling business unit of Verisk (Nasdaq: VRSK), a leading data analytics and technology provider to the global insurance industry, today released Verisk's 2026 Global Modeled Catastrophe Losses Report. The annual report calculates that the insurance industry should be prepared to withstand $171 billion in insured catastrophe losses on average in a given year, up $19 billion from a year ago, and the highest estimate Verisk has reported to date. The industry’s loss benchmark increased even after a year with no U.S. hurricane landfalls for the first time in a decade, and it reflects continued growth in property values and insured values worldwide.  

An integrated boost, Auto-pattern, and ultra-low operational current LED driver reduces both power and MCU overhead in compact battery-powered applications

RESTON, Va., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Regula, a global developer of identity verification solutions and forensic devices, has once again been named a winner in the Cybersecurity Blog category of the 2026 Cybersecurity Excellence Awards. This is the second consecutive year the blog has been recognized by the awards, following its 2025 Best Cybersecurity Blog title. The award honors the Regula Blog for turning complex developments and emerging trends in identity fraud prevention, biometrics, document authentication, digital identity, and forensic science into practical knowledge for cybersecurity professionals.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU AND UK MARKET ABUSE REGIMES

Total Voting Rights

Schiphol, September 1, 2026 - Aegon today published the agenda for its Extraordinary General Meeting of Shareholders (EGM) scheduled for October 8, 2026. The purpose of the EGM is to seek shareholder approval for Aegon’s redomiciliation to the US, as was announced at Aegon’s Capital Markets Day in December 2025.

Facility backed by seven-year contracted capacity agreement and estimated €1.0–1.7 billion in regional investment for local development and employment

BEIJING, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 37,679 vehicles in August 2026. As of August 31, 2026, Li Auto’s cumulative deliveries reached 1,801,834.

Free-to-Enter Program Recognizes Innovation in Education Technology Worldwide

Simon Cowley joins Health-ISAC to strengthen the organization’s global presence and engagement across Australia, New Zealand, and the Asia-Pacific region

Physician-led telehealth platform keeps compounded semaglutide and tirzepatide at one price from first dose through maintenance, with independent batch testing, one-to-two-day expedited delivery and $377 in nutrition, coaching and provider support included at no added cost.

Wilmington, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a live Innovation Day webcast for analysts and investors from Wilmington, Delaware on September 17, 2026. The event will provide an updated view of Ashland’s Technology Platforms, including their commercial progress and scalability.  Registration is required and can be accessed from the following link: innovationday26.ashland.com

CHICAGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Leadership communication expert David Grossman, founder and CEO of The Grossman Group and author of The Heart Work of Modern Leadership, is available for interviews following The Wall Street Journal’s report that EY is committing $100 million in bonuses to encourage employees to develop critical thinking, judgment and other “human” skills needed in the AI era.

MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Board, effective immediately.

WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple clinical programs, including an oral presentation of initial data from the RESTORE-PV trial of DISC-3405 in patients with polycythemia vera (PV), at the SOHO Annual Meeting, which will be held in Houston, Texas on September 9-12, 2026.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hertz (HTZ) To Contact Him Directly To Discuss Their Options

BOCA RATON, FL, Aug. 31, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company with a treasury strategy built around accumulating and compounding Solana (SOL), today announced that it intends to conduct an initial public offering registered under the Securities Act of 1933, as amended, of up to $20 million of shares of its Variable Rate Series C Perpetual Preferred Stock (the “CHAD Stock”). The Company also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of CHAD Stock offered in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Cogent (CCOI) To Contact Them Directly To Discuss Their Options

Miami Beach, FL, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Inflection Point Acquisition Corp. VIII (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the closing of its initial public offering of 28,750,000 units, which includes 3,750,000 units issued pursuant to the full exercise by the underwriters of their overallotment option at a price of $10.00 per unit, resulting in gross proceeds of $287,500,000. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. The units are listed on The Nasdaq Global Market, or Nasdaq, and began trading under the ticker symbol “IPHXU” on August 28, 2026. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “IPHX” and “IPHXW,” respectively.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Planet Fitness (PLNT) To Contact Him Directly To Discuss Their Options

Proposed combination pairs long-term minority ownership in NFL, NBA, MLB and NHL franchises with a sports intelligence business built to measure athlete value at scale to serve surging team, college/NIL, and brand demand; concurrent with signing, an investor group purchased a 19.9% stake at market price with no warrants

The first silicon spin quantum computer to operate in a shared commercial data center, bringing quantum computing a step closer to industry